Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Strategy analysis > Trends

Trends


loader
  • Sort by Custom
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Click to order products ascending
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • Big Pharma Licensing Trends, 2011–15

    $5,000.00

    Between 2011 and 2015, Big Pharma – a peer set of approximately 16 firms across the world with large R&D and sales organizations, and sales valued at $10bn or more – signed over 1,100 drug-focused deals, growing at a compound annual growth rate of 10%.

    October 14, 2016
    Find out more
  • Big Pharma Licensing Trends, 2012–16

    Big Pharma Licensing Trends, 2012–16

    $2,995.00

    Between 2012 and 2016, Big Pharma – a peer set of approximately 16 firms across the world with large R&D and sales organizations, and annual revenues in excess of $10bn – signed over 1,200 drug-focused deals, growing at a compound annual growth rate of 12%.

    March 8, 2017
    Find out more
  • Big Pharma Licensing Trends, 2014–18

    $2,995.00

    An analysis of the drug-focused licensing deals (out-licensing and in-licensing) made by Big Pharma companies shows an uptick in partnering from 2014 to 2015, followed by a slight decrease in 2016 that has held steady through 2018. Despite that slight decline, the peer set increased deal volume by roughly 15% between the beginning and the end of the five-year period. Total deal values rose even more, roughly 25%.

    August 20, 2019
    Find out more
  • Biosimilar Insulin Market Access

    Biosimilar Insulin Market Access

    $2,995.00

    Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants Toujeo and Tresiba. More aggressive payers are excluding branded insulin products in favor of the less expensive biosimilar, forcing switches in existing patient populations. As such, manufacturers of branded insulin products will need to offer deeper discounts to remain on payers’ formularies and contracts.

    June 19, 2017
    Find out more
  • Biosimilars Portfolio and Pipeline Trends, 2016

    $2,995.00

    Biosimilars are expected to drive significant cost savings for healthcare systems, yet there are many considerations that will affect the success of biosimilars, ranging from clinical development, regulatory approval, and ongoing legal disputes around patents. In the US, this is still a seminal period, and for that reason the potential effects of biosimilars in terms of levels of competition are still too early to gauge. Still, European experience with biosimilars may give an indication as to how market dynamics will play out and the degree to which biosimilar sponsors may discount their biosimilars in the US.

    November 23, 2016
    Find out more
  • catch-up-car-t-cover

    Catch Up On CAR-T

    $699.00
    Sale!

    With the approval of the first CAR-T therapies – Novartis’ Kymriah and Gilead/Kite’s Yescarta – what had been the promise of cutting-edge science is now reality.

    November 24, 2017
    Find out more
  • Data in Healthcare: Underpinning the Shift to Value

    $2,995.00

    Data plays a key role in healthcare systems’ shifts towards value-focused outcomes. Such data includes outcomes and cost data, adherence data, and increasingly, patient-reported data, behavioral and social media data.

    November 23, 2016
    Find out more
  • Datamonitor Healthcare Strategy: Immuno-Oncology Deal Trends, 2014–18

    $2,995.00

    Immuno-oncology continues to draw pharma companies to the deal table.

    August 5, 2019
    Find out more
  • From R&D Investment to Externalization: Where is the Pharma Industry Maximizing Value?

    $2,995.00

    Pharmaceutical companies are attempting to maximize value from all angles, including internal investment in R&D and externalization via deal-making.

    June 8, 2017
    Find out more
  • Gene Therapy Pipeline and Portfolio Analysis

    $3,000.00

    Gene therapy has undergone transformative enhancements over the last 20 years, with improvements to technologies and advances in the pipeline that aim to invigorate the field in its second generation.

    April 23, 2019
    Find out more
  • Immuno-Oncology Deal Trends, 2011–15

    $5,000.00

    Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated. The Big Pharma and Mid Pharma peer sets are an integral part of development and have been furthering efforts via deal-making.

    October 14, 2016
    Find out more
  • Immuno-Oncology Deal Trends, 2012–16

    Immuno-Oncology Deal Trends, 2012–16

    $2,995.00

    Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated.

    April 19, 2017
    Find out more
  • Innovation in Deal-Making

    $3,000.00

    In order to continually and effectively compete with its peers, as well as with smaller specialty pharmaceutical companies and biotechnology companies, the top 20 global pharmaceutical peer set turns to deal-making as a means to balance out its internally developed portfolio, and to take advantage of the broader capabilities of partners or takeover targets.

    June 13, 2018
    Find out more
  • Mid Pharma Outlook

    $3,000.00

    Total sales from the mid pharma peer set amounted to $69.4bn in 2011; by the end of 2012, this figure rose by 1.6% to $71.0bn. During 2012 the peer set constituents exhibited varying degrees of sales growth.

    September 28, 2016
    Find out more
  • New Pharma Models for a New Healthcare Era

    $2,995.00

    This analysis includes insights from eight interviewed experts from pharma, medical device, or digital health companies.

    December 20, 2018
    Find out more
Page 1 of 2
Page 1 of 212
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Datamonitor Healthcare is part of Pharma intelligence Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
  • Informa PLC
  • ABOUT US
  • INVESTOR RELATIONS
  • TALENT
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726
informa
Call Back
Scroll to top